TriZetto Sees $90 Mil. Revenue Stream From Erisco, IMS Subsidiary
Executive Summary
TriZetto could add around $90 mil. in incremental sales based on converting a portion of the customer base served by the Erisco subsidiary of IMS to a TriZetto application server provider contract, CEO Jeffery Margolis said during a May 18 teleconference.
You may also be interested in...
IMS Envisions e-DTC, Disease Management Products With TriZetto Merger
IMS Health sees its merger with Internet start-up TriZetto as a way to offer web-based products to the pharmaceutical industry, including electronic direct-to-consumer advertising and online disease management programs.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials